A consecutive series of 21 previously untreated patients with low-grade non-Hodgkin lymphomas were treated with mitoxantrone 5 mg/m2 daily for 3 days every 3 weeks. The cumulative dose did not exceed 165 mg/m2 in any patient. In this group, 7 patients had small lymphocytic lymphomas, 10 patients had follicular small cleaved cell lymphomas, and 4 patients had follicular mixed small-and large-cell lymphomas. Of the 21 patients, 20 obtained remission (complete in 6, partial in 14), and 15 of these are still in remission. Relapse-free survival is 68% at 2 years. None of the patients has died. Nonhematologic toxicity was modest. No severe alopecia was seen, and only 6 patients had nausea and vomiting (WHO grade 1–3). No cardiac toxicity was seen. In conclusion, mitoxantrone is a highly active and well-tolerated drug in this subset of patients. Hematologic toxicity, especially leukopenia, was dose limiting, and a reduction of the dose was necessary in 15 out of the 21 patients.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Coltman CA Jr, Coltman TM, Balcerzak SP, Morrison FS, Von Hoff DD (1984) Mitoxanthrone in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group Study. Semin Oncol 11 [Suppl 1]: 50–53
Ezdinli EZ, Anderson JR, Melvin F, Glick JH, Davis TE, O'Connell MJ (1985) Moderate versus aggressive chemotherapy of nodular poorly differentiated lymphoma. J Clin Oncol 3: 769–775
Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA (1986) Follicular lymphoma. Prognostic factors for response and survival. J Clin Oncol 4: 1470–1480
Gams RA, Keller JW, Golomb HM, Steinberg J, Dukart G (1983) Mitoxanthrone in malignant lymphomas. Cancer Treat Rev 10 [Suppl B]: 69–72
Gams RA, Steinberg J, Posner L (1984) Mitoxantrone in malignant lymphoma. Semin Oncol 11 [Suppl 1]: 47–49
Jones SE, Fuks Z, Bull M, Kadin ME, Dorfman RF, Kaplan HS, Rosenberg SA, Kim H (1973) Non-Hodgkin lymphoma IV. Clinicopathologic correlation in 405 cases. Cancer 31: 806–823
Peterson BA, Frizzera G, Anderson JR, Bloomfield CD, Pajak TF, Gottlieb AJ, Holland JF (1985) Response of low grade lymphomas to cyclophosphamide (CTX) or cyclophosphamide, adriamycin, vincristine, prednisone, and belomycin (CAVPB). Proc ASCO 4: C-822
Smith IE (1983) Mitoxantrone (Novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10: 103–115
Valdivieso M, Bedikian AY, Burgess MA, Savaraj N, Jeffers WB, Bodey GP (1981) Phase I clinical study of dihydroxyanthracenedione administered on a 5-day IV schedule. Cancer Treat Rep 65: 841–844
Van Echo DA, Whitacre MY, Aisner J, Wiernik PH (1981) Phase I trial of dihydroxyanthracenedione. Cancer Treat Rep 65: 831–834
Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr (1980) Phase I clinical investigation of 1,4-dihydroxy-5,8-bis[(2-(2-hydroxyethyl)amino]ethyl)amino)-9,10-anthracenedione dihydroxychloride (NSC 301739), a new anthracenedione. Cancer Res 40: 1516–1518
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva (WHO offset publication no. 48)
About this article
Cite this article
Hansen, S.W., Nissen, N.I., Hansen, M.M. et al. High activity of mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemother. Pharmacol. 22, 77–79 (1988). https://doi.org/10.1007/BF00254186
- Cell Lymphoma
- Cumulative Dose